Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLNCF) Income from Continuing Operations (2019 - 2025)

Historic Income from Continuing Operations for Silence Therapeutics (SLNCF) over the last 7 years, with Q3 2025 value amounting to -$21.0 million.

  • Silence Therapeutics' Income from Continuing Operations rose 4651.43% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 2320.54%. This contributed to the annual value of -$45.3 million for FY2024, which is 1562.71% up from last year.
  • Per Silence Therapeutics' latest filing, its Income from Continuing Operations stood at -$21.0 million for Q3 2025, which was up 4651.43% from -$27.4 million recorded in Q2 2025.
  • Silence Therapeutics' Income from Continuing Operations' 5-year high stood at $12.3 million during Q4 2024, with a 5-year trough of -$39.2 million in Q3 2024.
  • Moreover, its 5-year median value for Income from Continuing Operations was -$16.6 million (2021), whereas its average is -$16.5 million.
  • Per our database at Business Quant, Silence Therapeutics' Income from Continuing Operations soared by 16622.85% in 2024 and then tumbled by 56837.47% in 2025.
  • Quarter analysis of 5 years shows Silence Therapeutics' Income from Continuing Operations stood at -$15.1 million in 2021, then dropped by 16.64% to -$17.7 million in 2022, then decreased by 5.23% to -$18.6 million in 2023, then surged by 166.23% to $12.3 million in 2024, then tumbled by 270.36% to -$21.0 million in 2025.
  • Its Income from Continuing Operations stands at -$21.0 million for Q3 2025, versus -$27.4 million for Q2 2025 and -$28.5 million for Q1 2025.